Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion

Covid19 Clinical Trial

— IMPACTCOVID  

Official title:

Influence of Military Preventive Policy for reCruit Training on COVID-19 Seroconversion

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT04476680
• Other study ID #: 1070MODREC20
• Status: Recruiting
• Phase: N/A
• Start date: September 1, 2020
• Est. completion date: April 28, 2021

Study information

• Verified date: March 2021
• Source: Royal Centre for Defence Medicine
• Contact: David R Woods, MD
• Phone: 00441214158660
• Email: doctordrwoods[@]aol.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

This study is intended to address the association between vitamin D status and seroconversion to SARS-CoV-2 in healthy young adults. The primary aim of the study is to determine the rates of 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population with a wide spread of vitamin D concentrations. The secondary aims of this study are to explore: 1. Any effect of vitamin D status on symptomatic illness. 2. The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults. 3. The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time. 4. Where salivary Immunoglobulin A (IgA) may be used to provide an alternative/ complementary serological method 5. The effect (if any) of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs and iii) gender.

Description:

The primary aim of the study is to determine the rates of 'silent' seroconversion rates, consistent with asymptomatic transmission of SARS-CoV-2, in a young healthy adult population with a wide spread of vitamin D concentrations. The study will be conducted over 16 weeks in two populations: Service Personnel undertaking initial military training, who are supplementing with vitamin D (1000 IU/day D3 for 4 weeks, and 400 IU/d D3 as a maintenance dose), and civilian students who are not supplementing. We will recruit adults aged 18-30 years old. Military and civilian participants will be recruited respectively in Catterick and Leeds, UK to start in coincidence with the recommencement of Autumn semester. In accordance with our power calculation and anticipated drop-out rate, 450 volunteers will be recruited in each group. Data collected at baseline and after 5, 9, 12 and 16 weeks will include seroconversion status assessed from a validated Dried Blood Spot (DBS) method in conjunction with novel salivary antibody testing, plus structured questionnaire responses screening for Covid-19 symptoms. Physical and demographic characteristics and serum levels of vitamin D concentrations collected from participants at study entry will facilitate secondary aims in relation to exploring the influence of gender, ethnicity, body mass and body mass index (BMI) on asymptomatic seroconversion, as well as interactions with vitamin D status and supplementation.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 900
• Est. completion date: April 28, 2021
• Est. primary completion date: April 28, 2021
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: All
• Age group: 18 Years to 30 Years

Eligibility

Inclusion Criteria:

• Able to access the study sites at Leeds Beckett University's Headingley or City campuses, UK OR recruit at Infantry Training Centre, Catterick Garrison, UK
• In possession of an internet-enabled smart phone capable of receiving and responding to smartphone alerts.

Exclusion Criteria:

• Previously diagnosed with COVID-19 either by RT-PCR or serologically (either prior to the study or at initial baseline testing).
• Use of over-the-counter or prescribed vitamin D supplements currently or in the past month
• Condition conferring 'very high risk' or 'high risk' of severe COVID-19
• have had an organ transplant
• are having chemotherapy or antibody treatment for cancer, including immunotherapy
• are having an intense course of radiotherapy (radical radiotherapy) for lung cancer
• are having targeted cancer treatments that can affect the immune system (such as protein kinase inhibitors or PARP inhibitors)
• have blood or bone marrow cancer (such as leukaemia, lymphoma or myeloma)
• have had a bone marrow or stem cell transplant in the past 6 months, or are still taking immunosuppressant medicine
• are pregnant or intent on becoming pregnant during the anticipated study period
• have a learning disability
• have a lung condition (such as cystic fibrosis, asthma, COPD, emphysema or bronchitis)
• have heart disease (such as heart failure)
• have high blood pressure (hypertension)
• have diabetes
• have chronic kidney disease
• have liver disease (such as hepatitis)
• have a condition affecting the brain or nerves (such as Parkinson's disease, motor neurone disease, multiple sclerosis, or cerebral palsy)
• have a problem with the spleen or have had the spleen removed
• have a condition with high risk of getting infections (such as SCID, sickle cell, HIV, lupus or scleroderma)
• are taking medicine that can affect the immune system (such as steroids)
• are very obese (a BMI of 40 or above)

Related Conditions & MeSH terms

• Acute Respiratory Tract Infection
• Communicable Diseases
• Coronavirus Infections
• Covid19
• Infection
• Respiratory Tract Infections
• SARS-CoV Infection
• Severe Acute Respiratory Syndrome
• Vitamin D Deficiency

Intervention

Dietary Supplement:
• Vitamin D
Pure Encapsulations' manufacturing facility is a US Food and Drug Administration (FDA) inspected and NSF International Good Manufacturing Practices registered company.

Locations

Country	Name	City	State
United Kingdom	Infantry Training Centre Catterick	Catterick Garrison
United Kingdom	Headingley and City campuses, Leeds Beckett University	Leeds	Yorkshire

Sponsors (3)

Lead Sponsor	Collaborator
Royal Centre for Defence Medicine	Leeds Beckett University, Liverpool John Moores University

Country where clinical trial is conducted

United Kingdom, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Seroconversion	asymptomatic seroconversion for SARS-CoV-2	24 weeks
Primary	Interim analysis - seropositivity at 12 weeks	asymptomatic seroconversion for SARS-CoV-2	12 weeks
Secondary	Dried Blood Spot performance	Sensitivity and specificity of dried blood spot assay compared with venous blood serology	24 weeks
Secondary	Salivary IgA performance	Sensitivity and specificity of salivary IgA compared with venous blood serology	24 weeks
Secondary	Prevalence of SARS-CoV-2	The background 'point' prevalence and subsequent rate of increase in seropositivity for SARS-CoV-2 in healthy young adults.	24 weeks
Secondary	Change in seropositivity	The individual reductions in seropositivity to SARS-CoV-2 over time, and changes in seropositivity in a defined young adult population over time	24 weeks
Secondary	Change in seroconversion rate	The effect of vitamin D supplementation on seroconversion rates stratified by: i) level of baseline vitamin D 'deficiency/ insufficiency/ sufficiency' status; ii) extent of BMI-defined normal/overweight/obesity cut-offs, iii) gender iv) ethnicity	24 weeks